Arbutus Biopharma (ABUS) Non-Current Debt (2016 - 2017)
Arbutus Biopharma (ABUS) posted Non-Current Debt of $12.0 million for Q4 2017, little changed sequentially from $12.0 million in Q3 2017, and little changed YoY from $12.0 million in Q4 2016.
Arbutus Biopharma (ABUS) Non-Current Debt (2016 - 2017) Analysis & Trends
Arbutus Biopharma has reported Non-Current Debt for 2 years, with the latest figure at $12.0 million in Q4 2017.
- Quarterly Non-Current Debt changed 0.0% year-over-year to $12.0 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $12.0 million (changed 0.0% YoY) and the FY2017 annual result came in at $12.0 million, changed 0.0% from the prior year.
- Non-Current Debt held at $12.0 million in Q4 2017 per ABUS's latest filing, from $12.0 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $12.0 million in Q4 2016 and troughed at $12.0 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 12.00 Mn |
| Sep 30, 2017 | 12.00 Mn |
| Jun 30, 2017 | 12.00 Mn |
| Mar 31, 2017 | 12.00 Mn |
| Dec 31, 2016 | 12.00 Mn |